| Literature DB >> 30565887 |
Zhimin Luo1,2,3,4, Wujin Sun1,3, Jun Fang1, KangJu Lee1,3, Song Li1,5, Zhen Gu1,3,6, Mehmet R Dokmeci1,3,7, Ali Khademhosseini1,3,7,6,8,9.
Abstract
Biocompatible and bioresponsive microneedles (MNs) are emerging technology platforms for sustained drug release with a potential to be a key player in transdermal delivery of therapeutics. In this paper, an innovative biodegradable MNs patch for the sustained delivery of drugs using a polymer patch, which can adjust delivery rates based on its crosslinking degree, is reported. Gelatin methacryloyl (GelMA) is used as the base for engineering biodegradable MNs. The anticancer drug doxorubicin (DOX) is loaded into GelMA MNs using the one molding step. The GelMA MNs can efficiently penetrate the stratum corneum layer of a mouse cadaver skin. Mechanical properties and drug release behavior of the GelMA MNs can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA MNs is tested and the anticancer efficacy of the released drugs against melanoma cell line A375 is demonstrated. Since GelMA is a versatile material in engineering tissue scaffolds, it is expected that the GelMA MNs can be used as a platform for the delivery of various therapeutics.Entities:
Keywords: gelatin methacryloyl; microneedle; sustained release; transdermal drug delivery
Mesh:
Substances:
Year: 2018 PMID: 30565887 PMCID: PMC6588190 DOI: 10.1002/adhm.201801054
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933